ArticleNpj viruses2026
Strengthening diagnostic capacity for viral hemorrhagic fevers in Forest Guinea: advances in Lassa fever case detection.
Article in Npj viruses, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
36 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Viral hemorrhagic fevers (VHFs) remain a major public health threat in resource-limited settings. The 2014-2016 Ebola epidemic exposed critical gaps in laboratory preparedness and diagnostic capacity in most-at-risk countries, including Guinea. In order to implement sustainable in-country laboratory capacity for early detection and rapid response to VHF outbreaks, a decentralized diagnostics laboratory strengthening program started in the forested region of Guinea in Guéckédou (2017) and N'Zérékoré (2021). Between 2017 and 2024, a total of 4683 samples from suspected VHF cases were tested across the two laboratories. Of those, 47 (1%) were identified as positive for VHFs by molecular testing, including the 2021 Ebola virus disease resurgence and Marburg virus disease emergence samples, for which the laboratories supported rapid outbreak detection and response. Notably, 30 Lassa fever cases were laboratory-confirmed with a case fatality rate of 67.9%. Of those, 50.0% and 27.6% of the cases originating from the Guéckédou and N'Zérékoré prefecture, respectively. Prior to this program, Lassa fever detection in Guinea remained anecdotic. One case of yellow fever and one of dengue were also identified by molecular assays. The establishment of locally embedded laboratory capacity enhanced VHFs preparedness, surveillance, and response in Guinea, supporting Lassa fever epidemiology and health-system resilience.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.